Stockscreener 앱 받기
4.515
0.67%
0.025
전일 마감가:
$4.49
열려 있는:
$4.48
하루 거래량:
378.47K
Relative Volume:
0.27
시가총액:
$1.75B
수익:
$775.09M
순이익/손실:
$-58.68M
주가수익비율:
-34.05
EPS:
-0.1326
순현금흐름:
$64.06M
1주 성능:
+10.51%
1개월 성능:
+2.26%
6개월 성능:
-35.06%
1년 성능:
-30.99%
1일 변동 폭
$4.46
$4.605
1주일 범위
$4.05
$4.735
52주 변동 폭
$3.82
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
명칭
Goodrx Holdings Inc
전화
(855) 268-2822
주소
2701 OLYMPIC BOULEVARD, SANTA MONICA
GDRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.515 | 1.75B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
222.70 | 36.28B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
53.15 | 10.01B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
41.72 | 7.47B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
83.31 | 7.24B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.93 | 6.38B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-04 | 개시 | Mizuho | Neutral |
| 2024-08-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-08-10 | 업그레이드 | DA Davidson | Neutral → Buy |
| 2023-07-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 개시 | Citigroup | Buy |
| 2022-11-04 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-08-12 | 개시 | DA Davidson | Neutral |
| 2022-06-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-06-06 | 재개 | BofA Securities | Buy |
| 2022-06-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 개시 | Wells Fargo | Equal Weight |
| 2022-04-07 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Neutral |
| 2022-03-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 재확인 | Barclays | Overweight |
| 2022-03-01 | 재확인 | BofA Securities | Neutral |
| 2022-03-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-01 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 재확인 | Evercore ISI | Outperform |
| 2022-03-01 | 재확인 | Goldman | Buy |
| 2022-03-01 | 재확인 | JP Morgan | Underweight |
| 2022-03-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-03-01 | 재확인 | SVB Leerink | Outperform |
| 2022-01-07 | 개시 | Goldman | Buy |
| 2021-12-21 | 개시 | Stephens | Overweight |
| 2021-12-02 | 개시 | Jefferies | Buy |
| 2021-08-31 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-08-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 개시 | Robert W. Baird | Neutral |
| 2021-04-06 | 재개 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Guggenheim | Buy |
| 2020-11-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 개시 | Barclays | Equal Weight |
| 2020-10-19 | 개시 | BofA Securities | Neutral |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-10-19 | 개시 | Credit Suisse | Outperform |
| 2020-10-19 | 개시 | Deutsche Bank | Hold |
| 2020-10-19 | 개시 | Goldman | Neutral |
| 2020-10-19 | 개시 | JP Morgan | Neutral |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
| 2020-10-19 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 개시 | SVB Leerink | Outperform |
| 2020-10-19 | 개시 | UBS | Buy |
모두보기
Goodrx Holdings Inc 주식(GDRX)의 최신 뉴스
Truist Cuts Price Target on GoodRx Holdings to $5.50 From $6.50, Keeps Hold Rating - MarketScreener
GoodRx Announces Date for First Quarter 2025 Earnings Release an - GuruFocus
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call - Bluefield Daily Telegraph
GoodRx Sets Q1 Earnings Date: What Healthcare Investors Should Watch - Stock Titan
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform - Yahoo Finance
Levi & Korsinsky Notifies GoodRx Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineGDRX - ACCESS Newswire
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.18 Average Price Target from Brokerages - MarketBeat
GoodRx Stock Hits 52-Week Low at $4.09 Amid Market Challenges - Investing.com Australia
GoodRx Stock Hits 52-Week Low at $4.09 Amid Market Challenges By Investing.com - Investing.com South Africa
GoodRx (GDRX) Launches Digital Prescription Service with Hy-Vee - GuruFocus
GoodRx launches new e-commerce experience for prescriptions - Yahoo Finance
GoodRx Introduces New E-commerce Experience for Retail Pharmacies - Seeking Alpha
Allakos And 2 Other Promising Penny Stocks To Watch - simplywall.st
GoodRx Holdings: The Top 7 Influences on Its Performance for 2025 & the Future! - Smartkarma
GoodRx, PBM Price-Fixing MDL Set In Rhode Island - Law360
GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital - Yahoo Finance
Do Fundamentals Have Any Role To Play In Driving GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Stock Up Recently? - simplywall.st
GoodRx: Great Value For Patient Investors (Upgrade) (NASDAQ:GDRX) - Seeking Alpha
PBMs Hit With Antitrust Suit Over GoodRx Generics Program - Law360
GoodRx Strengthens Leadership: $100M Revenue Leader Takes President Role - StockTitan
GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by US Bancorp DE - Defense World
GoodRx Holdings, Inc. (GDRX): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock? - Insider Monkey
GoodRx Holdings, Inc. (GDRX): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
12 Cash-Rich Penny Stocks To Buy According To Hedge Funds - Insider Monkey
Shareholders of GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Wells Fargo & Company Cuts GoodRx (NASDAQ:GDRX) Price Target to $8.00 - Defense World
Levi & Korsinsky Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
GoodRx Holdings, Inc. (GDRX) Q4 Earnings Match Estimates - MSN
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2024 Earnings Call Transcript - MSN
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc.(GDRX) Shareholders - ACCESS Newswire
The Analyst Verdict: GoodRx Holdings In The Eyes Of 4 Experts - Benzinga
Investors who lost money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class ActionGDRX - ACCESS Newswire
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St
Decoding GoodRx Holdings Inc (GDRX): A Strategic SWOT Insight - GuruFocus.com
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales - Benzinga
GoodRx Holdings Inc (GDRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
GoodRx Holdings Reports Strong 2024 Financial Results - TipRanks
GoodRx Earnings Call: Growth Amid Challenges - TipRanks
Citi raises GoodRx stock target to $6.75, maintains buy rating By Investing.com - Investing.com South Africa
GoodRx Holdings IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
Citi raises GoodRx stock target to $6.75, maintains buy rating - Investing.com
Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics - MSN
Raymond James Reiterates Strong Buy Rating on GoodRx Holdings Inc. (GDRX) - StreetInsider.com
GoodRx Holdings Inc. (GDRX) PT Raised to $6.75 at Citi - StreetInsider.com
Goodrx Holdings Inc (GDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
3.05%
자본화:
|
볼륨(24시간):